Tiziana Life Sciences plc TLSA 深 滬
已收盤 07-18 16:00:00 美东时间
1.55
+0.040
+2.65%
華盛通- 最 高1.557
- 今 開1.50
- 成交量 17.50万股
- 最 低 1.48
- 昨 收 1.51
- 總市值 1.81亿
- 52周最高 1.91
- 市盈率 靜 --
- 換手率 0.15%
- 52周最低 0.6295
- 委 比 0.18%
- 總股本 1.17亿
- 歷史最高 24.30
- 量 比 1.50
- 振 幅 5.10%
- 歷史最低 0.41
- 每 手 1
- 風險率 0.23%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Tiziana shares rise on presentation date for foralumab data
Tiziana Life Sciences (NASDAQ:TLSA) shares rose on Friday after the company said that its CEO, Ivor Elrifi, will present data related to its lead drug candidate, intranasal foralumab, for the treatmen...
06-13 21:36
Tiziana Life Sciences to Present Intranasal Foralumab Findings at Bio International Convention
Tiziana Life Sciences ( ($TLSA) ) has provided an update. On June 13, 2025, Tiz...
06-13 20:58
12 Health Care Stocks Moving In Friday's Pre-Market Session
Gainers Prenetics Global (NASDAQ:PRE) shares moved upwards by 17.8% to $9.45 d...
06-13 20:11
Tiziana Life Sciences Expands Phase 2 Clinical Trial of Intranasal Foralumab with Commencement of First Patient Dosing at Weill Cornell Multiple Sclerosis Center
Tiziana Life Sciences announces the initiation of dosing at Weill Cornell Medicine Multiple Sclerosis Center for its Phase 2 clinical trial evaluating intranasal foralumab in patients with non-active Secondary Progressive Multiple Sclerosis (na-SPMS). This marks the fifth site added to the trial, which also includes Yale University, Johns Hopkins University, Brigham and Women's Hospital, and the University of Massachusetts. The Phase 2 trial aims...
06-13 14:30
Tiziana Life Sciences to Present at the Bio International Convention
Tiziana Life Sciences CEO Ivor Elrifi will present on the clinical findings of intranasal foralumab, a fully human anti-CD3 monoclonal antibody, at the Bio International Convention in Boston on June 18. Foralumab, the first fully human anti-CD3 mAb administered intranasally, targets neuroinflammatory and neurodegenerative diseases by modulating regulatory T cells. The Company is currently conducting a Phase 2 trial in non-active secondary progres...
06-13 12:30
Tiziana Life Sciences shares are trading higher after the company highlighted clinical progress for its intranasal alzheimer's therapy.
Tiziana Life Sciences shares are trading higher after the company highlighted c...
05-24 03:58
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers Tiziana Life Sciences (NASDAQ:TLSA) shares increased by 10.2% to $1.51...
05-23 05:05
Tiziana Life Sciences reports purchase of shares by chairman
Tiziana Life Sciences (NASDAQ:TLSA) on Monday said that its Executive Chairman and Founder, Gabriele Cerrone, has purchased 15,000 common shares at $1.55 per share, bringing his total holding to 43,25...
05-12 20:04
Tiziana posts favorable PET scan data for lead asset in Alzheimer's
Tiziana Life Sciences (NASDAQ:TLSA) announced Friday that PET scan data from a patient with moderate Alzheimer's disease who received its lead asset, intranasal foralumab, indicated a sharp decline in...
05-09 19:33
Tiziana rises on positive results in multiple sclerosis treatment study
Tiziana Life Sciences (NASDAQ:TLSA) reported positive results from a study of its nasal anti-CD3 antibody, foralumab, for non-active secondary progressive multiple sclerosis treatment. The company's s...
05-06 21:08
